-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

B of A Securities Downgrades Fate Therapeutics to Underperform, Lowers Price Target to $4

Benzinga · 01/06/2023 08:22
B of A Securities analyst Tazeen Ahmad downgrades Fate Therapeutics (NASDAQ:FATE) from Buy to Underperform and lowers the price target from $72 to $4.